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Introduction:  Treatment  of  non-small  cell  lung  cancer  (NSCLC)  is  an  important  and  often  unmet  medical
need  regardless  of  the  disease  stage  at the  time  of  ﬁrst diagnosis.  Antigen-speciﬁc  immunotherapy  may
be a  feasible  therapeutic  option  if tumor  associated  antigens  (TAAs)  that  can be targeted  by the  patient’s
immune  system  are  identiﬁed.  The  study  objective  (NCT01837511)  was  to investigate  the  expression
rates  of MAGE-A3  and  PRAME  in tumors  from  East  Asian  NSCLC  patients,  and  the  associations  between
TAA  expression  and  clinico-pathologic  patient  characteristics.
Methods:  Archived  formalin-ﬁxed  parafﬁn-embedded  tumor  tissue  specimens  were  tested  for  MAGE-
A3 and  PRAME  expression  by quantitative  reverse  transcription  polymerase  chain  reaction.  Exploratory
analyses  of  the  impact  of  patient  and  tumor  characteristics  on antigen  expression  were  performed  by
multivariate  logistic  regression  analyses.
Results:  A total  of 377  specimens  were  tested  and  a valid  expression  result  was obtained  for  86.5% and
92.6%  for  MAGE-A3  and PRAME,  respectively.  Of the specimens  with  valid  test results, 26.4%  expressed
MAGE-A3,  49.9%  PRAME,  20.0%  both  and  57.5%  expressed  at  least  one  TAA.  The  same  pattern  of associations
between  antigen  expression  and  patient  and  tumor  characteristics  was  found  for  both  TAAs:  higher  rates
of antigen-positive  tumors  were  found  in  squamous  cell  carcinomas  compared  to adenocarcinomas,  and
for smokers  compared  to non-smokers.
Conclusions:  Expression  of  MAGE-A3  and  PRAME  suggests  an association  with tumor  histology  and  the
patient’s  smoking  status.  The  rates  of  TAA-positive  tumors  found  in  these  East  and  South  East  Asian  NSCLC
patients  indicate  that both  antigens  may  serve  as  targets  for antigen-speciﬁc  immunotherapies.
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1. Introduction
Lung cancer is the most common cause of cancer death world-
wide [1]. Approximately 80% of all lung cancer cases are non-small
cell lung cancer (NSCLC), which are often fatal due to the ﬁrst diag-
nosis of about 60% of patients with advanced and usually incurable
disease [2].
3 Present address: Celyad, Mont-Saint-Guibert, Belgium.
4 Present address: Vionova-Biosciences, Lasne, Belgium.
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Table 1
Probe and primer sequences of the assays.
Name Sequence
MAGE-A3
MAGE-A3 probe FAM-CCT-GTG-ATC-TTC-AGC-AAA-MGB
MAGE-A3 forward TGT-CGT-CGG-AAA-TTG-GCA-GTA-T
MAGE-A3 reverse CAA-AGA-CCA-GCT-GCA-AGG-AAC-T
PRAME
PRAME probe FAM-TGC-TCA-GGC-ACG-TGA-T-MGB
PRAME forward GAG-GCC-GCC-TGG-ATC-AG
PRAME reverse CGG-CAG-TTA-GTT-ATT-GAG-AGG-GTT-T
-ACTIN38 S. Thongprasert et al. / Lu
More than 50% of patients with resectable NSCLC (stage I –
IIA) relapse within two years of complete surgical resection. Five-
ear survival rates range between 73% and 24% and decrease with
ncreasing pathological stage. The standard adjuvant therapy for
esected NSCLC patients is cisplatin-based chemotherapy, which
rovides limited clinical beneﬁt with a few percentage points
ncrease of the ﬁve-year survival rate [3]. Notably, toxicities leading
o patient withdrawals before the completion of the entire sched-
led treatment were observed in these trials, including increased
ardiac mortality [4].
Antigen-speciﬁc immunotherapy is a potential alternative treat-
ent option for NSCLC. This type of immunotherapy aims to
obilize the patient’s immune system to recognize and elicit a
trong and robust immune response against the tumor cells [3] and
as been shown to have an acceptable safety proﬁle compared to
hemotherapy and newer targeted molecular inhibitors [5]. Over
he last 25 years, several tumor-associated antigens (TAAs) have
een identiﬁed and partly characterized, including the Melanoma-
ssociated AntiGEn A3 (MAGE-A3) and the Preferentially expressed
ntigen of MElanoma (PRAME).
MAGE-A3 belongs to the cancer testis (CT) family of genes not
xpressed in normal adult cells except in the testis germ cells [6].
he lack of human leukocyte antigen class I cells on the surface
f germ cells implies that MAGE-A3 derived epitopes cannot be
resented to and recognized by T cells, so MAGE-A3 is consid-
red tumor-speciﬁc [7]. The presence of MAGE-A3 on tumor cells
as been associated with a poor prognosis [8–10], suggesting a
athogenic role in disease progression.
PRAME may  be characterized as an atypical CT antigen [11]:
nlike the others, it is expressed at low levels in certain cell types
n normal adult tissues other than the testis [12]. The PRAME
ntigen has a well-deﬁned immunogenicity and has been found
o induce speciﬁc killing of PRAME-expressing leukemia cells by
RAME-speciﬁc cytotoxic T-lymphocytes [13]. High levels of PRAME
xpression have been found to correlate with shorter overall sur-
ival in neuroblastoma [14] and serous ovarian adenocarcinomas
ACs) [15], and with poor clinical outcomes in breast cancer [16].
In view of the known ethnic differences between East Asian
nd Western populations [17–21], the purpose of this study was
o investigate the expression of MAGE-A3 and PRAME in tumors
rom East and South East Asian NSCLC patients with varying dis-
ase stages. A further aim was to perform exploratory multivariate
nalyses of associations between antigen expression and various
atient and tumor characteristics.
. Materials and methods
Approval of the study (ClinicalTrials.gov: NCT01837511) was
btained from each institutional ethics committee before any study
rocedure was performed.
The gene expression testing was performed in 2007 and 2008.
.1. Study cohort
This study was a multi-center, retrospective observational study
ased on the analysis of randomly selected archived, formalin-
xed, parafﬁn-embedded (FFPE) tumor tissue specimens (N = 377)
rom NSCLC patients in South Korea (N = 100), Singapore (N = 77),
aiwan (N = 100) and Thailand (N = 100). In addition to the FFPE tis-
ue specimens, information on patient and tumor characteristics
as recorded, including patient gender, age, smoking status, origin
f FFPE tissue (primary tumor or lymph node), tumor TNM stage,
istology and size (binary, 4 cm as threshold).Actin probe TGC-TCG-CTC-CAA-CC
Actin forward CTG-GAA-CGG-TGA-AGG-TGA-CA
Actin reverse CGG-CCA-CAT-TGT-GAA-CTT-TG
The criteria for inclusion of FFPE patient specimens were that
the patient had pathologically proven NSCLC (stage I, II or III) and
availability of all required clinico-pathological data.
2.2. Manual dissection
Manual dissection of the tumor specimens was performed by
Response Genetics Inc. (RGI, Los Angeles, CA, USA). Ten micron
thick sections were mounted on plain glass slides and stained with
nuclear fast red (NFR). Using a hematoxylin and eosin stained 5 m
thick section as a guide, a minimum of 50 mm2 of tumor tissue with
50–80% of neoplastic cells content (as required for the MAGE-A3
assay) was scraped off the NFR-stained slides and collected in a
micro-centrifuge tube.
2.3. Total RNA extraction
Total RNA was  extracted and puriﬁed from the manually dis-
sected FFPE specimens using a modiﬁed version of the RNeasy
FFPE kit (Qiagen, Hilden, Germany). To improve the elimination
of genomic DNA (gDNA), the kit procedure was modiﬁed by intro-
ducing an additional DNAse digestion step (MiniElute column for
15 min  at room temperature).
2.4. cDNA synthesis
Complementary DNA (cDNA) master-mix was  prepared by mix-
ing 1.5 L M-MLV  RT (Invitrogen, Carlsbad, CA, USA), 6 L 1 st
Strand buffer (5×), 3 L of 0.1 M DDT, 0.75 L bovine serum albu-
min  (BSA) (Invitrogen) diluted to 2.9 mg/mL, 3 L pre-mixed dNTP
(Applied Biosystems, Foster City, CA, USA), 0.3 L pd(N)6 random
hexamers (Roche Molecular Diagnostics, Pleasanton, CA, USA) and
0.75 L RNAse Inhibitor (Invitrogen). cDNA synthesis was per-
formed by mixing 15 L cDNA master-mix and 15 L RNA and
incubating 8 min  at 26 ◦C, 45 min  at 42 ◦C and 5 min  at 95 ◦C.
2.5. qRT-PCR assays
MAGE-A3 and PRAME genes along with ˇ-actin housekeep-
ing gene were ampliﬁed by quantitative reverse transcription
polymerase chain reaction (qRT-PCR) using the TaqMan chem-
istry (Thermo Fisher, Waltham, MA,  USA) on the ABI 7900
system (Applied Biosystems) in 384-well plates. Probe and primer
sequences are presented in Table 1.
The equivalent of 0.5 L puriﬁed RNA was ampliﬁed in a ﬁnal
volume of 20 L using the Gold Ampliﬁcation System (Applied
Biosystems) following the kit instructions. Primers and probes were
used at concentrations of 1.2 M and 0.2 M,  respectively. The
ampliﬁcation proﬁle was  1 cycle of 2 min  at 50 ◦C, 1 cycle of 12 min
at 95 ◦C, 46 cycles of 15 s at 95 ◦C and 1 min  at 60 ◦C.
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Table 2
Demographic and disease characteristics.
Total cohort (N = 377)
Characteristics Categories n % (95% CI)
Age (years) Less than 45 22 5.9 (3.7–8.7)
45–54 66 17.6 (13.8–21.7)
55–64 123 32.7 (27.9–37.6)
65–74 123 32.7 (27.9–37.6)
75 or more 42 11.2 (8.1–14.8)
Missing 1 –
Gender Female 130 34.8 (29.7–39.5)
Male 244 65.2 (59.7–69.5)
Missing 3 –
Origin of specimen Lymph node 2 0.5 (0.1–1.9)
Primary tumor 366 99.5 (94.8–98.5)
Missing 9 –
Stage IA 72 19.5 (15.3–23.4)
IB 134 36.3 (30.7–40.6)
IIA 17 4.6 (2.6–7.1)
IIB 57 15.4 (11.7–19.1)
IIIA 69 18.7 (14.5–22.6)
IIIB 20 5.4 (3.3–8.1)
Missing 8 –
Primary tumor size Less than 4 cm 201 54.9 (48.1–58.4)
More or equal than 4 cm 165 45.1 (38.7–48.9)
Missing 11 –
Histology Squamous cell carcinoma 124 32.9 (28.2–37.9)
Adenocarcinoma 211 56.0 (50.8–61.0)
Adenocarcinoma bronchoalveolar 20 5.3 (3.3–8.1)
Large cell carcinoma 8 2.1 (0.9–4.1)
Adenosquamous carcinoma 7 1.9 (0.7–3.8)
Undifferentiated carcinoma 7 1.9 (0.7–3.8)
Smoking Status Non-smoker 90 24.0 (19.7–28.5)
Smoker 85 22.7 (18.4–27.1)
Ex-smoker 94 25.1 (20.6–29.6)
NA 106 28.3 (23.6–32.9)
Missing 2 –
n/% = number/percentage of patients in a given category.
95% CI = 95% conﬁdence interval.
NA = Not available, meaning that the investigator on the data collection form had
ticked the box “information not available” for the patient’s smoking status at the time
of  tumor specimen sampling. “Missing” means that none of the response options forS. Thongprasert et al. / Lu
cDNA corresponding to 50 ng (100%) and to 0.5 ng (1%) of total
NA extracted from the human melanoma cell line MZ-2-3.0 (also
eferred to gene expression reference level (GERL) and provided
y Ludwig Institute of Cancer Research, Brussels, Belgium) was
ncluded in each PCR plate as positive control. To detect possi-
le PCR contamination, a negative control (H2O) was included in
ach test plate. To verify successful gDNA removal for the MAGE-
3 assay, a PCR without reverse transcriptase (RT) was performed
or all specimens.
.6. Calculation of tumor antigen expression levels
The relative antigen expression level within a tumor was  calcu-
ated by the formula:
elativetumorantigenexpressionlevel = 2(c-d)
here c = -actin cycle threshold (Ct) obtained from the equivalent
f 0.5 L of tumor RNA and d = tumor antigen Ct obtained from the
quivalent of 0.5 L of tumor RNA.
A tumor specimen was deﬁned as MAGE-A3 positive if the rel-
tive expression of MAGE-A3 to ˇ-actin in the biopsy was  ≥1% of
he relative expression of MAGE-A3 to ˇ-actin in the GERL cell line
4.96 E-5 copies of MAGE-A3 mRNA per copy of -actin mRNA).
or PRAME, tumor specimens with expression ≥0.3% of the relative
xpression of PRAME to ˇ-actin in the GERL cell line (1.73 E-4 copies
f PRAME mRNA per copy of -actin mRNA) were categorized as
RAME-positive.
Additional requirements for a specimen to be characterized as
ntigen positive were: 1) absence of PCR contamination using the
egative control; 2) positivity of the GERL cell line; 3) -actin Ct
30; 4) a difference ≤2 between the Ct-values of the replicates; 5)
bsence of gDNA contamination for MAGE-A3 by requiring a dif-
erence of minimum two cycles between the MAGE-A3 PCR with
nd without RT, respectively. For PRAME, a gDNA control was not
equired because the primers span the intron-exon boundaries.
The expression results are presented as the proportion of
ntigen-positive tumors among those with a valid test result for
he antigen; co-expression rates were determined for tumors with
alid tests for both antigens. PCR test results were deemed invalid
f there was gDNA contamination, inconsistent replicates or if
he specimen had a mean -actin Ct-value plus Ct exceeding
he assay’s limit-of-quantiﬁcation (those out-of-range specimens
ere ignored). A FFPE specimen was categorized as quantity-not-
ufﬁcient (QNS) if there was insufﬁcient tumor tissue to perform
he assay or if the amount of RNA extracted was insufﬁcient.
.7. Statistical analyses
Descriptive statistics are presented with associated 95% conﬁ-
ence intervals (CIs).
Univariate and multivariate logistic regression analyses were
erformed to determine the associations between antigen expres-
ion status as dependent variable and the patient and tumor
haracteristics as explanatory variables with control for the com-
ined effect of the factors.
. Results
Altogether 377 FFPE specimens were collected for antigen
xpression testing. Patient demographics, smoking status, and
umor characteristics are presented in Table 2. Tumor histology
as predominantly AC (56.0%) and squamous cell carcinoma (SCC)
32.9%), while occurrence of small and large tumors was  roughly
qual. Information on smoking status was unavailable for 28.3% of
he patients.this variable had been ticked.
Details about samples categorized as QNS and the reasons for
obtaining invalid assay results are provided in Table 3. 86.5%
(345/377) of samples gave a valid test result for MAGE-A3, 92.6%
(349/377) gave a valid result for PRAME, and 86.2% (325/377) gave
valid results for both antigens.
The overall levels of antigen-positive tumors were similar across
all four countries for both MAGE-A3 and PRAME, so here we report
and discuss the entire cohort without distinction between coun-
tries (Fig. 1). In total, from the samples with valid test results, 26.4%
(86/345) were MAGE-A3 positive, 49.9% (174/349) were PRAME-
positive (Table 4), 20.0% (65/325) were positive for both, and 57.5%
(187/325) positive for at least one of the antigens (data not shown).
The subset analyses of gene expression levels in various sub-
groups determined by patient and tumor characteristics indicated
several statistically signiﬁcant differences. The rates of MAGE-A3
and PRAME expression in subgroups are presented in Table 4, with
non-overlapping 95% CIs interpreted as indicators of statistically
signiﬁcant differences at the p = 0.05 level.
These ﬁndings were conﬁrmed by univariate logistic regression
analyses with antigen-expression status as the dependent variable
and the available patient and tumor characteristics as explanatory
variables. Only ACs and SCCs, representing 88.9% of the total cohort,
were included in these analyses.
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Table  3
Validity of MAGE-A3 and PRAME expression test.
Characteristics Categories n % (95% CI)
MAGE-A3
Validity test (N = 377) Valid 326 86.5 (82.6–89.8)
Invalid 29 7.7 (5.2–10.9)
QNS  22 5.8 (3.7–8.7)
Reason for PCR test invalidity (N = 29) Specimen out-of-range 24 82.8 (64.2–94.2)
Inconsistent replicates – –
gDNA contamination 5 17.2 (5.8–35.8)
PRAME
Validity  test (N = 377) Valid 349 92.6 (89.4–95.0)
Invalid 6 1.6 (0.6–3.4)
QNS  22 5.8 (3.7–8.7)
Reason for PCR test invalidity (N = 6) Specimen out-of-range 3 50.0 (11.8–88.2)
Inconsistent replicates 2 33.3 (4.3–77.7)
gDNA contamination 1a 16.7 (0.4–64.1)
QNS
Reason  for QNS (N = 22) Absence of tumor tissue 3 13.6 (2.9–34.9)
Not enough tumor tissue 13 59.1 (36.4–79.3)
Not enough RNA 6 27.3 (10.7–50.2)
N = Number of patients in total in a given characteristics.
n/% = Number/percentage of patients in a given category.
95% CI = 95% conﬁdence interval.
QNS = Quantity not sufﬁcient.
a This specimen was PRAME-negative but considered invalid because of a coding error. It is not taken into account for the calculation of PRAME expression rates.
Table 4
Expression of MAGE-A3 and PRAME overall and in subgroups deﬁned by patient and tumor characteristics.
Characteristics and categories MAGE-A3 PRAME
N n % (95% CI) N n %
Overall 326 86 26.4 (21.7–31.5) 349 174 49.9 (44.5–54.2)
Gender
Men  218 68 31.2 (25.1–37.8) 229 142 62.0 (55.4–68.3)
Women  105 16 15.2 (9.0–23.6) 117 30 25.6 (18.0–34.5)
Age  group (years)
less than 45 18 3 16.7 (3.6–41.4) 21 7 33.3 (14.6–57.0)
45  to 54 59 9 15.3 (7.2–27.0) 64 24 37.5 (25.7–50.5)
55  to 64 108 33 30.6 (22.1–40.2) 113 62 54.9 (45.2–64.2)
65  to 74 107 31 29.0 (20.6–38.5) 113 57 50.4 (40.9–60.0)
75  or more 33 10 30.3 (15.6–48.7) 37 23 62.2 (44.8–77.5)
Smoking status
Non-smoker 76 8 10.5 (4.7–19.7) 83 18 21.7 (13.4–32.1)
Smoker 73 19 26.0 (16.5–37.6) 78 58 74.4 (63.2–83.6)
Ex-smoker 82 31 37.8 (27.3–49.2) 86 53 61.6 (50.5–71.9)
Unknown 93 27 29.0 (20.1–39.4) 100 44 44.0 (34.1–54.3)
Tumor stage
IA 65 8 12.3 (5.5–22.8) 67 24 35.8 (24.5–48.5)
IB  117 37 31.6 (23.3–40.9) 124 63 50.8 (41.7–59.9)
IIA  10 2 20.0 (2.5–55.6) 13 6 46.2 (19.2–74.9)
IIB  48 16 33.3 (20.4–48.4) 53 30 56.6 (42.3–70.2)
IIIA  62 20 32.3 (20.9–45.3) 68 37 54.4 (41.9–66.5)
IIIB  16 2 12.5 (1.6–38.3) 16 11 68.8 (41.3–89.0)
Size  of the primary tumor
<4 cm 172 33 19.2 (13.6–25.9) 186 72 38.7 (31.7–46.1)
≥4  cm 144 52 36.1 (28.3–44.5) 152 96 63.2 (55.0–70.8)
Tumor histology
Adenocarcinoma 180 36 20.0 (14.4–26.6) 195 71 36.4 (29.7–43.6)
Adeno-broncho 17 2 11.8 (1.5–36.4) 17 4 23.5 (6.8–49.9)
Adenosquamous 7 2 28.6 (3.7–71.0) 7 0 0 (0.0–41.0)
Large  cell carcinoma 8 5 62.5 (24.5–91.5) 8 2 25.0 (3.2–65.1)
Squamous cell 110 40 36.4 (27.4–46.1) 116 93 80.2 (71.7–87.0)
Undifferentiated 4 1 25.0 (0.6–80.6) 6 4 66.7 (22.3–95.7)
N .
n ut of 
9
m = Number of patients in this subgroup with a valid test result for this tumor gene
/%  = Number/percentage of patients in this subgroup positive for this tumor gene o
5%  CI = 95% conﬁdence interval.
For MAGE-A3, the following odds-ratios (ORs) were found:
en  compared to women, OR = 2.5 (p = 0.003); non-smokers com-those with a valid gene expression test result.pared to current smokers, OR = 0.3 (p < 0.001); SCC compared to
AC, OR = 2.3 (p = 0.002); tumor size ≥4 cm compared to <4 cm,
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Fig. 1. Gene expression results by country (Total cohort) for MAGE-A3 (A) and PRAME (B). The y-axes show the specimens’ level of MAGE-A3 (PRAME) expression relative to
t mark t
(
O
i
i
(
b
mhe  MAGE-A3 (PRAME) expression in the GERL. The horizontal lines at 1.0% (0.3%) 
0.3%)  of the GERL MAGE-A3 (PRAME) expression.
R = 2.4 (p < 0.001). Age did not have a statistically signiﬁcant
mpact (p = 0.20) and tumor stage was not retained in the ensu-
ng multivariate model, despite a statistically signiﬁcant relation
p = 0.045), because the association had no clear direction (Table 4).Based on this and on investigation of all possible interactions
etween the signiﬁcant variables, a multivariate model was  for-
ulated taking into account the following factors: smoking status,he threshold for categorizing a specimen as MAGE-A3 (PRAME)-positive, i.e., 1.0%
tumor histology, tumor size and the interaction between tumor
histology and size. Gender was not retained in the ﬁnal model as
the apparent effect of gender was  likely linked to smoking sta-
tus. The estimated ORs for this multivariate model show that for
tumors <4 cm,  the rate of MAGE-A3 expression was much higher in
SCC tumors, while this difference was not found in larger tumors
142 S. Thongprasert et al. / Lung Can
Table  5
Odd Ratios for the ﬁnal multivariate models for the determinants of MAGE-A3
expression and PRAME expression.
MAGE-A3 expression
Factor Categories OR (95%CI)
Smoking status Ex-smokers vs smokers 1.7 (0.8–3.7)
No-smokers vs smokers 0.5 (0.2–1.8)
Interaction Histology –
size of tumor
<4 cm – squamous cell
carcinoma vs adenocarcinoma
8.3 (2.6–27.0)
≥4 cm – squamous cell
carcinoma vs adenocarcinoma
1.3 (0.5–3.4)
Squamous cell carcinoma –
≥4 cm vs <4 cm
0.7 (0.3–1.7)
Adenocarcinoma – ≥4 cm vs
<4 cm
4.2 (1.2–14.2)
PRAME expression
Factor Categories OR (95%CI)
Smoking status Ex-smokers vs smokers 0.6 (0.3–1.3)
No-smokers vs smokers 0.2 (0.1–0.5)
Histology Squamous cell carcinoma vs
adenocarcinoma
6.9 (3.4–13.8)
OR = Odds ratio.
95% CI = 95% conﬁdence interval.
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immunotherapeutic as adjuvant therapy of completely resectedTable 5). For ACs, larger tumors had a higher rate of MAGE-A3
xpression, while tumor size had no impact for SCC tumors.
For PRAME, the univariate logistic regression analyses gave
he following ORs: men  compared to women, OR = 4.7 (p < 0.001);
on-smokers compared to current smokers, OR = 0.1 (p < 0.001);
CC compared to AC, OR = 7.6 (p < 0.001); tumor ≥4 cm compared
o <4 cm,  OR = 2.7 (p < 0.001). Age (p = 0.052) and tumor stage
p = 0.112) were not retained in the multivariate logistic regression
nalysis.
A multivariate model was formulated taking into account these
actors: gender, smoking status, histology, tumor size and any pos-
ible interactions between these. Analysis of this model showed
hat smoking status and histology remained independent signiﬁ-
ant factors, so only these were retained in the ﬁnal model, with
he estimated ORs presented in Table 5. Non-smokers were signiﬁ-
antly less likely to be PRAME-positive than smokers, regardless of
umor histology, while the rate of PRAME-positive was  higher for
CC than for AC tumors regardless of the patient’s smoking status.
. Discussion
The study demonstrated the feasibility of testing the expres-
ion of MAGE-A3 and PRAME by means of dedicated antigen-speciﬁc
RT-PCR assays performed on mRNA extracted from archived FFPE
issues. The rates of valid results were high for both MAGE-A3
86.5%) and PRAME (92.6%) assays. For both antigens, invalid tests
ere mostly due to results being outside the linear range of the
ssays.
Studies reporting MAGE-A3 expression in Asian NSCLC tumors
ave been previously published (e.g., [8,22–24]) and during the
reparation of the present manuscript a study testing MAGE-A3
nd PRAME in Chinese NSCLC patients was published [25]. For both
ntigens, the expression rates found in our sample of NSCLC tumors
ere similar to those reported in the previous studies but the range
f rates of MAGE-A3 positive was wide, varying from 23.8% [24] to
5% [8]. A common ﬁnding of all these antigen expression studies
s that MAGE-A3 and PRAME are expressed in SCC tumors approx-
mately twice as much as in AC tumors.cer 101 (2016) 137–144
The univariate regression analyses with antigen expression as
the dependent variable, and the available patient and tumor char-
acteristics as explanatory factors showed the same pattern for
MAGE-A3 and PRAME.  The lowest rates of MAGE-A3 and PRAME
expression were observed in tumors from three patient subsets
(women, non-smokers, AC tumors) who  in other studies have
been found to have the highest prevalence of speciﬁc activating
mutations of the epidermal growth factor receptor (EGFR) gene
[26,27], which makes them likely to respond to treatment with
small molecule tyrosine kinase inhibitors (EGFR-TKIs) [26]. It would
therefore be interesting to carry out additional tumor marker
studies to investigate correlations between EGFR mutations and
expression of MAGE-A3 and PRAME.
The multivariate logistic regression analyses exploring possible
determinants of antigen expression showed for both antigens, that
the signiﬁcant factors when controlling for all the other study vari-
ables were patient smoking status and tumor histology (AC versus
SCC). For MAGE-A3, the model also included an interaction between
tumor histology and size.
The observed association between smoking and expression of
MAGE-A3 and PRAME may  be explained by the effect of exposure to
tobacco smoke on DNA methylation. By impacting the DNA-protein
interaction involved in DNA transcription, DNA methylation may
modify the transcription of DNA to RNA and inhibit DNA transcrip-
tion if it occurs in a gene promoter region while having a stimulating
effect in the context of gene bodies [28]. In several studies reviewed
by Lee and colleagues, current smoking has been associated with
reduced DNA methylation of different genes and related increases
in the expression of these genes [28]. However, none of these
studies have actually investigated MAGE-A3 and PRAME.  Without
relating it to the methylation status of the gene promoter region,
Bhutani et al. [29] detected expression of MAGE-A3 in normal
bronchial cells of 31% of former chronic smokers without cancer.
This ﬁnding suggests that chronic exposure to cigarette smoke acti-
vates MAGE-A3 and other members of the MAGE family (-A1 and
-B2) even before malignant transformation of the bronchial cells
[29].
There is evidence of considerable differences in the character-
istics of NSCLC patients in East Asian and Western populations:
younger age at onset and a higher proportion of patients who
have never smoked in East Asian patients [17], more toxicity
of chemotherapy in East Asian patients [18], and differences in
response rates and survival [19–21]. There are also ethnic dif-
ferences in the rate of activating EGFR mutations. Numerous
epidemiological and genetic studies to clarify the reasons for these
differences have been or are being performed, but results are not
considered conclusive [17]. Therefore, it was interesting to com-
pare the observations of the present study with the ﬁndings of a
German study of 1260 tumors from NSCLC patients using the same
assays for testing of FFPE specimens [30].
Based on TAA expression rates for the total patient samples of
each study, MAGE-A3 and PRAME were more commonly expressed
in German tumors compared to East and South East Asian tumors,
36% versus 26% for MAGE-A3 and 66% versus 50% for PRAME.  How-
ever, these differences were considerably reduced when the two
histology subsets were compared separately, in particular for SCC
tumors where rate of PRAME expression was the same for Asian
and European tumors. These ﬁndings underline the importance of
taking all relevant factors into account when comparing different
ethnic groups, including inter-ethnic variations in the prevalence
of AC and SCC tumors in NSCLC patients.
Recently, a large Phase III study of a MAGE-A3-basedMAGE-A3-positive NSCLC patients failed to show improved
disease-free survival compared to placebo, despite promising Phase
II trial results and convincing data for immunological response
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31,32]. Comprehensive investigations have not led to the elucida-
ion of the reasons for a negative result. However, it is speculated
hat the immunological response measured in peripheral blood,
n particular the antigen-speciﬁc antibodies and antigen-speciﬁc
ymphocytes, may  not be sufﬁciently translated to the peri-tumor
tromal immune system because of a highly immunosuppressive
umor microenvironment [32].
The MAGE-A3 immunotherapeutic was part of a research
rogram developing antigen-speciﬁc cancer immunotherapeu-
ics, including one targeting PRAME. This research program has
ow been stopped. However, an alternative option might be to
ombine immunization with monoclonal antibodies that reverse
he immunosuppressive microenvironment and have shown very
ong-lasting response in patients with advanced NSCLC [32,33].
. Conclusions
In summary, these results suggested an association in NSCLC
atients between the expression of MAGE-A3 and PRAME with the
haracteristics of patients and tumors. In particular, smoking status
nd tumor histology were correlated with the rate of expression
or both TAA. These associations may  have an impact on treatment
nd, should be taken into account during the clinical development
f antigen-speciﬁc cancer immunotherapeutic compounds.
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